
Clifford Chance, a law firm founded in London, announced on Tuesday that it has added two partners based in Washington, D.C. from Baker Botts. Among them is the co-leader of Baker Botts’ life sciences antitrust team.
William Lavery and Joseph Ostoyich have been announced as the representatives for large public and private companies in antitrust investigations and litigation by the firm. Clifford Chance has appointed Ostoyich, who was previously an executive committee member at Baker Botts in Houston, to head their U.S. antitrust litigation practice.
Clifford Chance announced that Lavery specializes in government investigations and has represented clients such as Exxon Mobil Corporation, Merck & Co., Inc., and Toyota Motor Corp. in federal courts and before the U.S. Department of Justice’s antitrust division and the Federal Trade Commission.
Read more:Clifford Chance Hires Two Antitrust Litigation Pros
Ostoyich has served as the primary trial lawyer in multiple cases and has provided representation for notable clients such as Exxon Mobil Corporation, AT&T Inc., and Colfax Corp.
According to a statement by Marc Besen, global co-head of antitrust at Clifford Chance, the inclusion of Lavery and Ostoyich will aid clients in addressing the growing assertiveness of global antitrust enforcement.In recent months, there have been changes among antitrust partners. Milbank recently hired a former U.S. Federal Trade Commission competition official and an attorney from the U.S. Justice Department in Washington.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas